A Double-Blind, Parallel Design Study to Determine the Effectiveness of Inspra (Eplerenone) in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure (The PREDICT Study)
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms PREDICT
- 24 Jan 2017 Status changed to discontinued due to lack of eligible patients.
- 07 Oct 2006 New trial record.